High-dose IL-2

DRUG2 trials

Sponsors

Providence Health & Services, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Conditions

Carcinoma, Renal CellMetastatic MelanomaSecondaryVaccination

Phase 2

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

Active, not recruitingNCT01416831

Providence Health & ServicesMetastatic Melanoma

Start: 2011-07-01End: 2026-12-01Updated: 2026-04-24

Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC

WithdrawnNCT03226236

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSCarcinoma, Renal Cell, Secondary, Vaccination

Start: 2016-03-31End: 2019-03-31Updated: 2018-11-13

Related Papers

Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer2020-05-0144 citations

Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy

Journal for ImmunoTherapy of Cancer2017-04-0778 citations